AmbAgon Therapeutics is a developer of cancer molecule therapeutics.
AmbAgon Therapeutics has raised $5.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in February 2025.
AmbAgon Therapeutics's investors include AbbVie, RA Capital Management, Inkef, Mission BioCapital, MRL Ventures Fund.
AmbAgon Therapeutics is headquartered in San Francisco, United States.
AmbAgon Therapeutics is a developer of cancer molecule therapeutics.
AmbAgon Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AmbAgon Therapeutics — Funding & Investors." VCBacked, February 7, 2025, https://www.vcbacked.co/company/ambagon-therapeutics. Accessed September 25, 2026.
VCBacked. (2025). AmbAgon Therapeutics — Funding & Investors. Retrieved September 25, 2026, from https://www.vcbacked.co/company/ambagon-therapeutics
{{cite web |title=AmbAgon Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/ambagon-therapeutics |website=VCBacked |access-date=September 25, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated